基本信息
views: 0
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Xiaobing Wu, Ph.D., female, born in 1965. Expertise in viral vectors and gene therapy. Engaged in virus vector research in the State Key Laboratory of Viral Genetic Engineering, Institute of Virology, Chinese Academy of Preventive Medicine for 15 years, and had won the second prize of National Science and Technology Progress Award, the first prize of Science and Technology Progress Award of the Ministry of Health, and the second prize of Beijing Science and Technology Achievement Award for his achievements in virus vectors. pubilished more than 40 academic papers related to researching viral vectors or the appilications. In 2014, Dr Wu founded the non-profit organization Beijing Ruicy Institute of Gene Therapy Technology for Rare Diseases. In 2018, She initiated Beijing Genecradle Therapeutics Inc. focusing on developing AAV gene therapy products for monogenetic diseases.
Research Interests
Papers共 144 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
MOLECULAR THERAPYno. 1 (2024): 59-73
Xiuwei Ma,Lu Zhuang, Wenhao Ma, Jun Li, Xiaodong Wang, Zhongqiu Li, Xinyang Jiang,Yongxia Wang, Ying Du, Yingqian Zhang, Fang He, Zhiming Zhu,
Chinese medical journal (2024)
Wang Wei,Mao Yingying, Zheng Ping,Cheng Peidi,Zhang Wenchao,Wu Xiaobing,Ma Wenhao,Chen Qian,Zhang Xue
Jun-Kai Tan, Ying Xiao,Guo Liu,Long-Xiang Huang, Wen-Hao Ma, Yan Xia,Xi-Zhen Wang,Xian-Jun Zhu,Su-Ping Cai,Xiao-Bing Wu,Yun Wang,Xu-Yang Liu
Load More
Author Statistics
#Papers: 147
#Citation: 2599
H-Index: 23
G-Index: 47
Sociability: 6
Diversity: 2
Activity: 0
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn